UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

      For quarterly period ended March 31, 2005

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

      Commission File No.  000-30991



             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


       NEVADA                               87-0458170
(State of incorporation)       (I.R.S. Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [ ]

As of May 9, 2005 Skinovation Pharmaceutical Incorporated had a total of
708,000 shares of common stock issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]


<PAGE>

                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1.  Financial Statements.............................................. 2

Item 2.  Plan of Operation................................................. 8

Item 3.  Controls and Procedures........................................... 8

                    PART II: OTHER INFORMATION

Item 6.  Exhibits.......................................................... 9

Signatures................................................................. 9



                 PART I:   FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS

The financial information set forth below with respect to our statements of
operations for the three month periods ended March 31, 2005 and 2004 is
unaudited.  This financial information, in the opinion of management, includes
all adjustments consisting of normal recurring entries necessary for the fair
presentation of such data.  The results of operations for the three month
period ended March 31, 2005 are not necessarily indicative of results to be
expected for any subsequent period.

                                2
<PAGE>










             Skinovation Pharmaceutical Incorporated

                       Financial Statements

                          March 31, 2005





                                3
<PAGE>





             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                          Balance Sheets

                              ASSETS
                              ------

                                                      March 31    December 31
                                                        2005          2004
                                                   ------------- -------------
                                                    (Unaudited)

CURRENT ASSETS

 Cash                                              $      2,869  $      3,037
                                                   ------------- -------------

  TOTAL ASSETS                                     $      2,869  $      3,037
                                                   ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY
               -----------------------------------

CURRENT LIABILITIES

Accounts Payable - Related party                   $     33,776  $     33,776
Advances payable - Other                                  5,900         5,168
                                                   ------------- -------------
  Total Liabilities                                      39,676        38,944
                                                   ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares
  issued and outstanding                                    708           708

Additional Paid in Capital                               25,148        25,148

Deficit Accumulated During the Development Stage        (62,663)      (61,763)
                                                   ------------- -------------

  Total Stockholders' Equity                            (36,807)      (35,907)
                                                   ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $      2,869  $      3,037
                                                   ============= =============









                                4
<PAGE>



             Skinovation Pharmaceutical Incorporated
                  (A Development Stage Company)
                     Statement of Operations
                           (Unaudited)

                                                                From
                                                                Inception on
                                For the         For the         January 15,
                                three months    three months    1988
                                ended March 31, ended March 31, to March 31,
                                2005            2004            2005
                                --------------- --------------- --------------

REVENUES                        $            -  $            -  $      27,937
                                --------------- --------------- --------------
EXPENSES
  General & Administrative                 900               -        127,675
                                --------------- --------------- --------------

    TOTAL EXPENSES                         900               -        127,675
                                --------------- --------------- --------------

NET LOSS BEFORE DISCONTINUED
  OPERATIONS                                 -               -        (99,738)

GAIN ON DISPOSAL OF OPERATIONS               -               -         37,075
                                --------------- --------------- --------------

NET INCOME (LOSS)               $         (900) $            -  $     (62,663)
                                =============== =============== ==============

NET LOSS PER SHARE              $            -  $            -  $       (0.18)
                                =============== =============== ==============
WEIGHTED AVERAGE SHARES
  OUTSTANDING                          708,000         708,000        383,785
                                =============== =============== ==============



                                5

<PAGE>




             Skinovation Pharmaceutical Incorporated
                   (A Development Stage Company)
                     Statement of Cash Flows
                           (Unaudited)

                                                                 From
                                                                 Inception on
                                      For the three months ended January 15,
                                                March 31,        1988 Through
                                      -------------------------- March 31,
                                           2005         2004     2005
                                      ------------- ------------ -------------
Cash Flows from Operating Activities

  Net Loss                            $       (900) $         -  $    (62,663)
  Less Non-cash Items:
   Shares issued for services                    -            -        10,433
   Shares issued for debt payment                -            -         1,424
   Increase in accounts payable                732            -        39,676
   Loss on disposal of PP&E                      -            -         5,263
                                      ------------- ------------ -------------
  Net Cash Provided (Used) by
  Operating Activities                        (168)           -        (5,867)
                                      ------------- ------------ -------------
Cash Flows from Investing Activities
  Cash paid for PP&E                             -            -        (5,264)
                                      ------------- ------------ -------------
  Net Cash Provided (Used) by
  Investing Activities                           -            -        (5,264)
                                      ------------- ------------ -------------
Cash Flows from Financing Activities
  Cash paid for offering costs                   -            -        (7,000)
  Common stock issued for cash                   -            -        21,000
                                      ------------- ------------ -------------
  Net Cash Provided (Used) by
  Financing Activities                           -            -        14,000
                                      ------------- ------------ -------------

Increase (Decrease) in Cash                   (168)           -         2,869

Cash and Cash Equivalents at
  Beginning of Period                        3,037            -             -
                                      ------------- ------------ -------------
Cash and Cash Equivalents at
  End of Period                       $      2,869  $         -  $      2,869
                                      ============= ============ =============

Supplemental Cash Flow Information:

  Stock issued for debt payment       $          -  $         -  $      1,424
  Stock issued for services           $          -  $         -  $     10,433

  Cash Paid For:
    Interest                          $          -  $         -  $          -
    Income Taxes                      $          -  $         -  $          -


                                6

<PAGE>

             Skinovation Pharmaceutical Incorporated
                Notes to the Financial Statements
                          March 31, 2005


GENERAL
-------

Skinovation Pharmaceutical Incorporated (the Company) has elected to omit
substantially all footnotes to the financial statements for the three months
ended March 31, 2005 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2004.

UNAUDITED INFORMATION
---------------------

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.


                                7
<PAGE>


In this report references to "Skinovation," "we," "us," and "our" refer to
Skinovation Pharmaceutical Incorporated.

        SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions.  This report contains
these types of statements.  Words such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology
used in connection with any discussion of future operating results or
financial performance identify forward-looking statements.  You are cautioned
not to place undue reliance on the forward-looking statements, which speak
only as of the date of this report.  All forward-looking statements reflect
our present expectation of future events and are subject to a number of
important factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.

ITEM 2.  PLAN OF OPERATION

During the next twelve months our management intends to actively seek an
operating company to acquire or merge with which may provide operating
revenue.  Based on current economic and regulatory conditions, management
believes that it is possible, if not probable, for a company like ours,
without many assets or liabilities, to negotiate a merger or acquisition with
a viable private company.  The opportunity arises principally because of the
high legal and accounting fees and the length of time associated with the
process of "going public."  However, should a merger or acquisition prove
unsuccessful, it is possible that we may decide not to pursue further
acquisition activities and management may abandon its activities and our
shares would become worthless.

As of the date of this filing, we have not identified any assets or business
opportunities for acquisition.  Potential investors must recognize that
because of limited capital available for investigation of business
opportunities and management's limited experience in business analysis, we may
not discover or adequately evaluate adverse facts about any business
opportunity to be acquired.  All risks inherent in new and inexperienced
enterprises are inherent in our plan.

It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

As of March 31, 2005 we had $2,869 cash on hand and total current liabilities
of $39,676.  The majority of our operating expenses are related to our
reporting obligations under the Exchange Act.  These expenses include legal,
accounting and professional services required to prepare our reports and the
costs of filing the reports with the SEC.  We are unable to pay cash for these
services and have relied on related parties to pay for these costs on our
behalf.  These parties have not entered into written agreements guaranteeing
advances and, therefore, they are not obligated to provide funds in the
future.  However, management anticipates that these parties will continue to
pay for these costs on our behalf during the next twelve months.
Historically, we have paid for these advances by converting the debt into
common stock.

ITEM 3.  CONTROLS AND PROCEDURES

Our President, who acts in the capacity of principal executive officer and
principal financial officer, has concluded that the disclosures related to the
effectiveness of our disclosure controls and procedures and our internal
control over financial reporting made in our annual report on Form 10-KSB,
filed March 30, 2005, remain accurate.

                                8


<PAGE>


                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS

Part I Exhibits

31.1  Principal Executive Officer Certification
31.2  Principal Financial Officer Certification
32.1  Section 1350 Certification

Part II Exhibits

3.1   Articles of Incorporation as amended  (Incorporated by reference to
      exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)
3.2   Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
      Form-SB, filed July 11, 2000)




                            SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                             SKINOVATION PHARMACEUTICAL INCORPORATED

                              /s/ John W. Peters
Date: May 11, 2005       By: ________________________________________
                             John W. Peters
                             President, Principal Executive Officer,
                             Principal Financial Officer, and Director





                                9